Martha Holtje

Array ( [id] => 15524881 [patent_doc_number] => 20200054746 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-20 [patent_title] => METHODS FOR INCREASING NEURONAL SURVIVAL [patent_app_type] => utility [patent_app_number] => 16/663038 [patent_app_country] => US [patent_app_date] => 2019-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18431 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16663038 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15360849 [patent_doc_number] => 20200016189 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-16 [patent_title] => METHOD FOR TREATING SCHIZOPHRENIA [patent_app_type] => utility [patent_app_number] => 16/584338 [patent_app_country] => US [patent_app_date] => 2019-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32169 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16584338 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16564456 [patent_doc_number] => 10889817 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-12 [patent_title] => Oligonucleotide therapy for Leber Congenital Amaurosis [patent_app_type] => utility [patent_app_number] => 16/576853 [patent_app_country] => US [patent_app_date] => 2019-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 11291 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16576853 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17370418 [patent_doc_number] => 20220025470 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => USE OF PROBES TO DETECT TOXIC ALGAE, DETECTION METHOD AND CORRESPONDING KITS [patent_app_type] => utility [patent_app_number] => 17/277020 [patent_app_country] => US [patent_app_date] => 2019-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54730 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17277020 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17850504 [patent_doc_number] => 20220280545 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-08 [patent_title] => COMPOUNDS AND METHODS FOR MODULATING CLN3 EXPRESSION [patent_app_type] => utility [patent_app_number] => 17/274981 [patent_app_country] => US [patent_app_date] => 2019-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32684 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17274981 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19060372 [patent_doc_number] => 11939582 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-26 [patent_title] => Antisense oligonucleotides targeting SCN2A for the treatment of SCN1A encephalopathies [patent_app_type] => utility [patent_app_number] => 17/269706 [patent_app_country] => US [patent_app_date] => 2019-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 7 [patent_no_of_words] => 23011 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 114 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17269706 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15408691 [patent_doc_number] => 20200024667 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-23 [patent_title] => MIRNA BASED TREATMENT MONITORING IN MULTIPLE SCLEROSIS [patent_app_type] => utility [patent_app_number] => 16/542837 [patent_app_country] => US [patent_app_date] => 2019-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 65203 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16542837 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16868477 [patent_doc_number] => 20210161944 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-03 [patent_title] => METHODS FOR TARGETING PAIN DIRECTED AT METABOLIC PATHWAYS [patent_app_type] => utility [patent_app_number] => 17/258544 [patent_app_country] => US [patent_app_date] => 2019-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10972 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17258544 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15681835 [patent_doc_number] => 20200095581 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-26 [patent_title] => MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPODYSTROPHY POPULATIONS [patent_app_type] => utility [patent_app_number] => 16/528387 [patent_app_country] => US [patent_app_date] => 2019-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34101 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16528387 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15342587 [patent_doc_number] => 20200009185 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-09 [patent_title] => METHOD FOR MAINTAINING INCREASED INTRACELLULAR p53 LEVEL, INDUCED BY PLATINUM-BASED ANTICANCER DRUG, AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 16/521459 [patent_app_country] => US [patent_app_date] => 2019-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8870 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 232 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16521459 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16091203 [patent_doc_number] => 20200199588 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => Polycomb-Associated Non-Coding RNAs [patent_app_type] => utility [patent_app_number] => 16/518623 [patent_app_country] => US [patent_app_date] => 2019-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46996 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16518623 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15294125 [patent_doc_number] => 20190390198 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-26 [patent_title] => METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF APLHA-1 ANTITRYPSIN BY DOUBLE-STRANDED RNA [patent_app_type] => utility [patent_app_number] => 16/457394 [patent_app_country] => US [patent_app_date] => 2019-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 100979 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16457394 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17604273 [patent_doc_number] => 11332746 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2022-05-17 [patent_title] => Compounds and methods for reducing LRRK2 expression [patent_app_type] => utility [patent_app_number] => 16/972822 [patent_app_country] => US [patent_app_date] => 2019-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 68186 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16972822 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14991063 [patent_doc_number] => 20190314489 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-17 [patent_title] => CELLS FOR PRODUCING INFLUENZA VIRUS AND METHOD FOR PRODUCING INFLUENZA VIRUS [patent_app_type] => utility [patent_app_number] => 16/453464 [patent_app_country] => US [patent_app_date] => 2019-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6398 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16453464 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17035081 [patent_doc_number] => 20210252039 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-19 [patent_title] => COMPOUNDS AND METHODS FOR INCREASING STMN2 EXPRESSION [patent_app_type] => utility [patent_app_number] => 16/973652 [patent_app_country] => US [patent_app_date] => 2019-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20213 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16973652 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16976149 [patent_doc_number] => 20210220386 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-22 [patent_title] => EXON SKIPPING OLIGOMERS AND OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY [patent_app_type] => utility [patent_app_number] => 16/972676 [patent_app_country] => US [patent_app_date] => 2019-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40517 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 113 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16972676 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15365959 [patent_doc_number] => 20200018744 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-16 [patent_title] => METHOD FOR DETECTING miRNA-206 FOR ANALYZING THE DIAGNOSIS OR PROGNOSIS OF A MENTAL ILLNESS BY A MOOD DISORDER, METHOD FOR PROVIDING INFORMATION FOR THE DIAGNOSIS, AND A COMPOSITION FOR TARGETING miRNA-206 [patent_app_type] => utility [patent_app_number] => 16/440196 [patent_app_country] => US [patent_app_date] => 2019-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5810 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16440196 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17792460 [patent_doc_number] => 20220251551 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY [patent_app_type] => utility [patent_app_number] => 16/973464 [patent_app_country] => US [patent_app_date] => 2019-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48620 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16973464 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18492403 [patent_doc_number] => 11697814 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-07-11 [patent_title] => Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene [patent_app_type] => utility [patent_app_number] => 16/437224 [patent_app_country] => US [patent_app_date] => 2019-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 88 [patent_figures_cnt] => 16 [patent_no_of_words] => 26830 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 143 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16437224 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15364191 [patent_doc_number] => 20200017860 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-16 [patent_title] => Therapeutic Agents [patent_app_type] => utility [patent_app_number] => 16/432645 [patent_app_country] => US [patent_app_date] => 2019-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13962 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16432645 [rel_patent_id] =>[rel_patent_doc_number] =>)